Option Care Health, Inc. (OPCH) - 10-Q Summary
Business Context and Reporting Period
This Quarterly Report on Form 10-Q covers the period ended June 30, 2026. Option Care Health, Inc. operates as a single segment providing infusion therapy and ancillary healthcare services through a national network of 86 full-service pharmacies and 187 ambulatory infusion suites. The company serves patients in home and non-hospital settings, contracting with managed care organizations, third-party payers, and hospitals.
Key Financial Metrics (Six Months Ended June 30, 2026)
| Metric | Value (in thousands) | YoY Change |
|---|---|---|
| Net Revenue | $2,793,054 | +1.6% |
| Gross Profit | $529,265 | -0.5% |
| Gross Margin | 18.9% | -50 bps |
| Operating Income | $157,685 | -2.6% |
| Net Income | $99,256 | +2.0% |
| Diluted EPS | $0.64 | +8.5% |
| Operating Cash Flow | $171,485 | +106.3% |
| Cash & Equivalents | $193,767 | -16.7% (vs. Dec 31, 2025) |
| Total Debt (Net) | $1,158,820 | -0.7% |
| Available Liquidity | $846,000 | Revolver capacity |
Material Changes vs. Prior Period
- Revenue Growth: Driven by high single-digit growth in the acute therapy portfolio. The chronic portfolio declined slightly due to patient attrition and unfavorable therapy mix in the Chronic Inflammatory Disease (CID) segment, partially offset by growth in Immunoglobulin/Neuro and rare/orphan therapies.
- Margin Compression: Gross profit margin decreased from 19.4% to 18.9% due to therapy mix shifts and continued headwinds in the CID portfolio. Management expects CID dynamics to negatively impact gross profit by approximately $55 million in 2026.
- Operating Expenses: Selling, general, and administrative (SG&A) expenses remained flat year-over-year due to lower performance-based compensation and cost management initiatives, offset by investments in strategic growth.
- Cash Flow Improvement: Operating cash flow surged to $171.5 million (from $83.1 million in the prior year) primarily due to reduced inventory levels resulting from supply chain optimization.
- Share Repurchases: The company repurchased $167.5 million of common stock in the first half of 2026, compared to $150.0 million in the same period of 2025.
Guidance, Outlook, and Risks
- Outlook: Management anticipates continued negative impact on gross profit from the CID portfolio throughout 2026. Investments in internal resources and technology are expected to drive future revenue growth and profitability.
- Liquidity: The company increased its Revolver Facility capacity to $850.0 million in March 2026. As of June 30, 2026, $846.0 million remains available. Management believes existing cash and credit facilities are sufficient for the next 12 months.
- Risks: Key risks include reimbursement rate changes from government programs (Medicare/Medicaid), payer concentration (largest payer represents ~14% of revenue), and potential supply chain disruptions. Legal proceedings and unclaimed property audits remain ongoing contingencies.
- Unusual Items: "Other, net" income improved significantly due to the absence of a prior-year accrual for an unclaimed property voluntary disclosure agreement (VDA) related to pre-merger BioScrip operations.
Investor Verification Checklist
- Verify the sustainability of the $55 million gross profit headwind attributed to the CID portfolio.
- Monitor the impact of the increased Revolver Facility capacity on future leverage ratios and interest expense.
- Assess the effectiveness of inventory management initiatives in maintaining the improved operating cash flow trend.
- Review the status of the unclaimed property VDA and any potential future liabilities related to pre-merger operations.
- Track the execution of the $1.0 billion share repurchase program and its impact on diluted share count.